Interestingly, while no significant correlation was observed in ovarian cancer patients at early stages of the disease (I and II), patients at stages III and IV with high FOLR2 expression had a significantly shorter median survival as compared with patients whose tumors had low expression of FOLR2 (Fig. 7e). The gene discussed is FOLR2; the disease is ovarian cancer.